[HTML][HTML] Laboratory parameters are possible prognostic markers in patients with advanced-stage NSCLC treated with bevacizumab plus chemotherapy
M Svaton, J Blazek, G Krakorova, M Buresova… - Journal of …, 2021 - ncbi.nlm.nih.gov
Purpose: To investigate potential associations between selected laboratory markers (CRP,
LDH, albumin, sodium, hemoglobin, neutrophils, and neutrophils/lymphocytes ratio [NLR]) …
LDH, albumin, sodium, hemoglobin, neutrophils, and neutrophils/lymphocytes ratio [NLR]) …
Next generation sequencing analysis and its benefit for targeted therapy of lung adenocarcinoma
…, M Svaton, T Vanecek, M Buresova… - Cancer Genomics & …, 2023 - cgp.iiarjournals.org
Background/Aim: Targeted therapy has become increasingly important in treating lung
adenocarcinoma, the most common subtype of lung cancer. Next-generation sequencing (NGS) …
adenocarcinoma, the most common subtype of lung cancer. Next-generation sequencing (NGS) …
Combination of circulating tumour DNA and 18F-FDG PET/CT for precision monitoring of therapy response in patients with advanced non-small cell lung cancer: a …
…, M Minarik, P Hosek, M Buresova… - Cancer Genomics & …, 2022 - cgp.iiarjournals.org
Background/Aim: Circulating tumour DNA (ctDNA) represents an emerging biomarker in non-small
cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron …
cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron …
Prognostic role for CYFRA 21-1 in patients with advanced-stage NSCLC treated with bevacizumab plus chemotherapy
…, G Krakorova, M Pesek, M Buresova… - Anticancer …, 2021 - ar.iiarjournals.org
Aim: To investigate potential associations between selected oncomarkers [carcinoembryonic
antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell …
antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell …
[HTML][HTML] Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC
M Buresova, L Benesova, M Minarik, R Ptackova… - Journal of …, 2023 - ncbi.nlm.nih.gov
Purpose: To investigate potential association between selected tumor markers and
laboratory parameters (lactate dehydrogenase [LDH], neutrophils, hemoglobin, neutrophils, …
laboratory parameters (lactate dehydrogenase [LDH], neutrophils, hemoglobin, neutrophils, …
[HTML][HTML] Worse Prognosis in the Symptomatic Patients With Lung Cancer–Czech Multicentric Study
…, M Jirousek, J Krejci, D Krejci, M Buresova… - Cancer Diagnosis & …, 2022 - ncbi.nlm.nih.gov
Results The most common symptoms were cough (47.5%), dyspnea (45.6%), pain (27.3%),
and weight loss (25.7%). Among all patients, 16% were asymptomatic. We demonstrated the …
and weight loss (25.7%). Among all patients, 16% were asymptomatic. We demonstrated the …
[PDF][PDF] Neo/adjuvantní imunoterapie v léčbě nemalobuněčného plicního karcinomu
M Svatoň, J Blažek, M Burešová… - Vnitřní …, 2022 - casopisvnitrnilekarstvi.cz
Despite improvements in staging, surgical techniques, and the introduction of adjuvant
chemotherapy for stage II and III nonsmall cell lung cancer (NSCLC), a large number of operated …
chemotherapy for stage II and III nonsmall cell lung cancer (NSCLC), a large number of operated …
Neo/adjuvant immunotherapy in the treatment of nonsmall cell lung cancer.
M Svatoň, J Blažek, M Burešová, J Vodička - Vnitrni Lekarstvi, 2022 - europepmc.org
Despite improvements in staging, surgical techniques, and the introduction of adjuvant
chemotherapy for stage II and III nonsmall cell lung cancer (NSCLC), a large number of operated …
chemotherapy for stage II and III nonsmall cell lung cancer (NSCLC), a large number of operated …
System NATURA 2000 utilization for purposes of biotope valuation
P Cudlín, M Prokopová, T Francírková, R Buresová - Ekológia, 2005 - search.proquest.com
RENATA BUREŠOVÁ, TOMÁŠ SMRŽş, EVA BOUCNÍKOVÁ … PAVELCUDLÍN, MARCELA
PROKOPOVÁ, TEREZA FRANCÍRKOVÁ, RENATA BUREŠOVÁ, TOMÁŠ SMRŽş, EVA …
PROKOPOVÁ, TEREZA FRANCÍRKOVÁ, RENATA BUREŠOVÁ, TOMÁŠ SMRŽş, EVA …
Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting
J Cumova, L Kovarova, A Potacova, I Buresova… - International journal of …, 2010 - Springer
Plasma cells (PCs) enrichment from bone marrow samples of multiple myeloma (MM) patients
is frequently performed by immunomagnetic separation (magnetic activated cell sorting, …
is frequently performed by immunomagnetic separation (magnetic activated cell sorting, …